Mechanism of Action of Apixaban
Apixaban is a selective, reversible, direct inhibitor of factor Xa (FXa) that prevents the conversion of prothrombin to thrombin, thereby reducing thrombus formation without requiring antithrombin III for its anticoagulant activity. 1
Primary Mechanism
Apixaban exerts its anticoagulant effect by selectively inhibiting factor Xa and prothrombinase activity, which prevents the conversion of prothrombin into thrombin 2. This mechanism is distinct from warfarin (which inhibits vitamin K-dependent clotting factor synthesis) and from heparin (which requires antithrombin III).
The drug inhibits both free factor Xa in plasma and clot-bound factor Xa, as well as factor Xa within the prothrombinase complex 3, 1. This comprehensive inhibition across different states of factor Xa is a key feature that distinguishes it from some other anticoagulants.
Secondary Effects on Coagulation
By inhibiting factor Xa, apixaban decreases thrombin generation and subsequent thrombus development 1. While apixaban has no direct effect on platelet aggregation, it indirectly inhibits thrombin-induced platelet aggregation by reducing thrombin formation 1. This indirect effect on platelets contributes to its overall antithrombotic activity.
Pharmacodynamic Consequences
The inhibition of factor Xa results in:
- Prolongation of clotting tests (PT, INR, aPTT), though these changes are small, highly variable, and not useful for monitoring 1
- Concentration-dependent increase in anti-FXa activity, which correlates closely with plasma apixaban concentration 1, 4
- Predictable anticoagulant effects without the need for routine coagulation monitoring 3
Clinical Relevance
The mechanism allows for fixed dosing without therapeutic drug monitoring in most patients, as the pharmacodynamic effect is predictable and dose-proportional 3. The drug's selective action on factor Xa, combined with its reversible binding, provides a favorable balance between efficacy and safety compared to traditional anticoagulants like warfarin 2, 5.
The oral bioavailability is approximately 45-50% 3, 1, with peak plasma concentrations occurring 3-4 hours after administration and a half-life of approximately 12 hours 2, 1. This pharmacokinetic profile supports twice-daily dosing for most indications.